Country: UNITED STATES | Region: NORTH AMERICA | Type: Cost Effectiveness | Keywords: #clinicalevidence #icer #prescriptiondrugs #pricechanges #priceincreases
- The Institute for Clinical and Economic Review (ICER) published its protocol for its upcoming “Unsupported Price Increase” (UPI) report in which the institute will examine significant price increases for prescription drugs and determine if new evidence is needed to support the increases
- ICER’s report will focus on up to 13 prescription drugs that experienced the most significant price increase in the U.S. over a one-year period and the Institute will base its decision on which net price increases had the most significant budget impact on the U.S. health system
- In its 2019 UPI report, ICER assessed AbbVie’s Humira (adalimumab), Pfizer’s Lyrica (pregabalin), Gilead’s Truvada (tenofovir disoproxil fumarate and emtricitabine), Genentech/Roche’s Rituxan (rituximab), Amgen’s Neulasta (pegfilgrastim), Eli Lilly’s Cialis (tadalafil), and Tecfidera (dimethyl fumarate), Gilead’s Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide), and Celgene’s Revlimid (lenalidomide)
THE DETAILS
BOSTON, Massachusetts, The United States – The Institute for Clinical and Economic Review (ICER) published its protocol for its upcoming “Unsupported Price Increase” (UPI) report in which the institute will examine significant price increases for prescription drugs and determine if new evidence is needed to support the increases.
ICER’s report will focus on up to 13 prescription drugs that experienced the most significant price increase in the U.S. over a one-year period. The Institute will base its decision on which net price increases had the most significant budget impact on the U.S. health system.
Initially, ICER is obtaining a list of the 100 drugs with the largest net sales in the U.S. The manufacturers of the top 15 drugs will be contacted by ICER, who will inform them that their product will potentially be up for review.
From this list, ICER will select 10 drugs for review based on pricing data and ICER will consider three additional drugs pending public feedback. When it comes to the additional three drugs, ICER is considering products with extremely high price increases that impact the budget on a national level or those used by millions of Americans with price increases that fell just below two times the medical CPI, among other factors.
ICER will review any updated clinical evidence to assess whether it supports a price increase for the drugs in question.
In its 2019 UPI report, ICER assessed AbbVie’s blockbuster Humira (adalimumab), Pfizer’s Lyrica (pregabalin), Gilead’s Truvada (tenofovir disoproxil fumarate and emtricitabine), Genentech/Roche’s Rituxan (rituximab), Amgen’s Neulasta (pegfilgrastim), Eli Lilly’s Cialis (tadalafil), and Tecfidera (dimethyl fumarate), which were noted as drugs with price increases unsupported by new clinical evidence, as well as Gilead’s Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) and Celgene’s Revlimid (lenalidomide), which were deemed as drugs with price increases with new clinical evidence.
Public input on the three additional drugs will be accepted by ICER until July 17, 2020.
Learn more about Pricentric ONE and our Global Pricing Solutions!
Contact us with your questions and global pricing needs, and an expert will follow up shortly.